Bioventures 2014 L.P. Mpm Sells 86,936 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 86,936 shares of the stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $1.43, for a total value of $124,318.48. Following the sale, the insider owned 6,355,717 shares of the company’s stock, valued at approximately $9,088,675.31. The trade was a 1.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total value of $145,976.32.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total value of $208,072.00.
• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total value of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total value of $125,059.48.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock remained flat at $1.31 during trading hours on Monday. The company’s stock had a trading volume of 712,892 shares, compared to its average volume of 494,803. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30. The stock’s fifty day moving average price is $1.62 and its 200 day moving average price is $1.32. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.52. The firm has a market cap of $59.91 million, a price-to-earnings ratio of -0.80 and a beta of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. Analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently modified their holdings of the stock. MPM Asset Management LLC raised its holdings in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the period. MPM Bioimpact LLC raised its holdings in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after purchasing an additional 20,799 shares during the period. Bank of America Corp DE raised its holdings in Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares during the period. Jane Street Group LLC bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at $409,000. Finally, Marshall Wace LLP bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at $113,000. Institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on HOWL. Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. JMP Securities dropped their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Finally, Bank of America dropped their target price on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.